12:01 PM
 | 
Dec 06, 2018
 |  BC Extra  |  Clinical News

Conatus down on Phase IIb NASH miss

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) lost $2.56 (57%) to $1.94 on Thursday after it said all three doses of emricasan missed the primary endpoint of improving mean hepatic venous pressure gradient (HVPG) from...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >